The estimated Net Worth of Bros. Advisors Lp Baker Bro... is at least 102 百万$ dollars as of 14 May 2021. Bros Bro owns over 40,000 units of Neoleukin Therapeutics stock worth over 102,377,461$ and over the last 5 years Bros sold NLTX stock worth over 0$.
Bros has made over 2 trades of the Neoleukin Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Bros exercised 40,000 units of NLTX stock worth 758,800$ on 14 May 2021.
The largest trade Bros's ever made was buying 3,017,542 units of Neoleukin Therapeutics stock on 20 December 2019 worth over 25,347,353$. On average, Bros trades about 611,508 units every 102 days since 2019. As of 14 May 2021 Bros still owns at least 29,334,516 units of Neoleukin Therapeutics stock.
You can see the complete history of Bros Bro stock trades at the bottom of the page.
Over the last 5 years, insiders at Neoleukin Therapeutics have traded over 425,653$ worth of Neoleukin Therapeutics stock and bought 6,490,231 units worth 38,477,971$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Group, Llc Green Jeremy Red...、Bros. Advisors Lp667, L.P.B.... On average, Neoleukin Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of 593,084$. The most recent stock trade was executed by Bros. Advisors Lp667, L.P.B... on 15 August 2023, trading 2,285,342 units of NLTX stock currently worth 1,462,619$.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Neoleukin Therapeutics executives and other stock owners filed with the SEC include: